Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study (S40.004)

Key Points

• The study aims to compare the efficacy and safety of fenebrutinib and ocrelizumab in treating primary progressive multiple sclerosis.
• Randomized trial comparing fenebrutinib and ocrelizumab in adult patients.
• Included patients diagnosed with primary progressive multiple sclerosis.
• Fenebrutinib demonstrated improved efficacy over ocrelizumab in the primary endpoint (specific metrics not provided).
• Both treatments were found to be safe, with no significant differences in adverse events reported.